查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971573

慢性阻塞性肺病和氣喘治療設備市場：按設備類型、適應症、最終用戶和分銷管道分類 - 全球預測 2026-2032 年

COPD & Asthma Devices Market by Device Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年，慢性阻塞性肺病（COPD）和氣喘治療設備的市值為396.9億美元，預計2026年將達到420.7億美元，到2032年將達到600.8億美元，複合年成長率為6.09%。

主要市場統計數據
基準年 2025 396.9億美元
預計年份：2026年 420.7億美元
預測年份 2032 600.8億美元
複合年成長率 (%) 6.09%

本報告對該行業進行了引人入勝的概述，闡述了影響當今 COPD 和氣喘管理的醫療設備的創新、臨床期望和醫療保健服務壓力。

隨著臨床需求和技術創新不斷融合，呼吸設備產業正處於關鍵的轉折點，慢性呼吸系統疾病的治療模式也隨之重塑。設備機制、氣溶膠科學和數位化藥物管理技術的進步，正拓展吸入和霧化系統的功能，使其不再局限於簡單的藥物輸送，而是成為監測、個人化治療和療效評估的綜合工具。臨床醫生日益需要設備收集數據，以輔助調整藥物劑量、評估病情加重風險並製定遠距醫療路徑；而患者則希望獲得關於設備易用性、便攜性和正確使用方法的清晰反饋。

對改變 COPD 和氣喘治療設備在醫療保健系統中的開發、部署和整合的關鍵結構性變化進行詳細分析。

近年來，突破性變革徹底改變了慢性阻塞性肺病（COPD）和氣喘設備的研發、應用和報銷方式。首先，數位化整合已從差異化因素轉變為核心需求。連網吸入器、配備感測器的儲霧槽以及基於雲端的用藥依從性平台，如今都對採購決策和臨床路徑產生重要影響。這種轉變要求產品開發團隊從設計初期就必須考慮軟體生態系統、網路安全和資料互通性，並制定包含韌體更新和資料管治在內的全生命週期策略。

對 2025 年美國關稅政策將如何重塑整個呼吸設備價值鏈的採購、生產決策和分銷策略進行策略分析。

美國在2025年實施的新關稅措施，使得製造商、供應商和經銷商迫切需要重新評估其國際採購和貿易依賴型成本結構。為此，許多企業正在加快近岸外包步伐，推動產品重新舉措以替換受關稅影響的零件，並重新談判供應商契約，以確保在保證產品性能和合規性的同時實現盈利。這些調整並非只是權宜之計，它們會影響工程設計選擇和庫存管理策略，進而影響前置作業時間和生產柔軟性。

透過分析設備、臨床、使用者和分銷環節之間的細微差異，我們可以確定產品設計和商業性重點可以創造競爭優勢的領域。

細分市場分析揭示了不同設備類型、適應症、最終用戶和分銷管道的需求趨勢、臨床考慮和設計重點。按設備類型分類，重點關注乾粉吸入器、定量噴霧吸入器、霧化器、緩霧吸入器以及帶儲霧罐和閥門的儲霧罐。霧化器創新涵蓋噴射式、網式和超音波式等亞型，每種類型在易用性、維護性和氣溶膠性能方面各有優劣，從而影響醫護人員的偏好和患者的用藥依從性。根據適應症，氣喘和慢性阻塞氣喘(COPD) 的臨床路徑需要劑量計數器和呼吸作用機制等特殊功能，而某些 COPD 管理方案則更傾向於持續輸注和長時間霧化。按最終用戶分類，診所、居家照護和醫院環境對設備的耐用性、感染控制和維護性的要求各不相同，其中居家照護尤其需要直覺的介面和遠端監測支援。根據通路的不同，醫院藥房、線上藥房和零售藥房各自需要獨特的包裝、標籤和實施策略。此外，電子商務的興起迫使製造商重新思考直接送藥給患者、保固支援和數位支援材料。這些細分觀點明確了產品差異化、臨床證據和商業性執行在哪些領域最為有效。

區域比較評估：確定地理因素對臨床實務、法規環境和供應鏈佈局的影響，並分析醫療設備的採用和市場策略。

區域性研究重點在於地理因素如何影響呼吸設備的臨床實踐、法規環境和商業模式。在美洲，與醫療系統和支付方的談判中，成本控制和可驗證的療效是重點，因此，能夠顯著提高用藥依從性和減少急診就診的呼吸設備更受青睞。該地區主要契約製造的存在支持了本地生產和快速分銷。在歐洲、中東和非洲，不同的監管環境和報銷機制要求企業採取靈活的市場進入策略。對公共衛生基礎設施的大量投資為支持大規模用藥依從性計劃和利用遠端醫療進行疾病管理的呼吸設備創造了機會。在亞太地區，快速的都市化、不斷成長的中產階級和強大的本地製造能力促進了規模設計方法和具有競爭力的定價策略。同時，對數位化醫療應用的投資也推動了對互聯設備和遠端監測解決方案的濃厚興趣。

對競爭與合作趨勢的深入評估，定義了成熟公司、利基創新者和數位領域的新進者如何塑造呼吸設備生態系統。

慢性阻塞性肺病和氣喘治療器材領域的競爭格局呈現出多元化的格局，既有傳統醫療設備製造商，也有專業吸入器開發商、電子健康技術開發商和靈活的契約製造(CMO)。老牌製造商繼續利用其臨床關係、監管經驗和規模經濟來維護現有基本客群，而專業公司則憑藉獨特的性能特徵、符合人體工學的設計和快速的產品改進週期展開競爭。數位健康領域的參與企業和專注於感測器技術的公司正在重新定義藥物依從性測量和基於行為科學的干涉措施的預期，而老牌公司則在尋求合作、授權或開發自有數位平台以保持競爭力。

優先考慮可操作的跨職能建議，將設備創新和供應鏈韌性轉化為永續的臨床部署和商業性成果。

產業領導者應採取策略措施，將技術潛力轉化為可衡量的臨床和商業性成果。首先，優先考慮模組化產品架構，以實現快速組件更換和區域客製化，從而降低貿易中斷風險並加快監管申報。其次，投資於整合式數位化解決方案，將設備硬體與用藥依從性分析和臨床醫生儀表板連接起來，以製定能夠捕捉真實世界療效和與支付方相關的衛生經濟學終點的循證方案。第三，透過認證關鍵組件的多個供應商，並考慮建立區域組裝基地，實現製造和採購網路多元化，從而縮短前置作業時間並提高應對力。

透過採用高度透明和嚴謹的混合調查方法，結合臨床醫生參與、監管分析和供應鏈映射，我們提供了切實可行的見解和建議。

本分析的調查方法結合了與關鍵相關人員的直接對話和全面的二手資料研究，以確保獲得平衡且實用的見解。一手資料研究包括對臨床醫生、呼吸治療師、採購經理、設備工程師和分銷合作夥伴進行結構化訪談，以收集關於設備性能、易用性和配銷通路趨勢的實際觀點。這些訪談用於檢驗關於臨床工作流程、用藥依從性障礙和採購優先事項的假設，並輔以實地考察，觀察設備在診所、醫院和居家醫療機構的部署。

明確的結論是：整合設備、數位化和供應鏈策略是決定 COPD 和氣喘治療長期成功的機制。

總而言之，受技術整合、護理模式演變以及貿易相關供應鏈壓力的影響，慢性阻塞性肺病（COPD）和氣喘治療設備的格局正在重塑。這些設備正從單一功能的給藥工具轉變為慢性病照護生態系統的組成部分，這需要在產品工程、臨床證據產生和商業運作之間制定協調一致的策略。數位化預期、居家照護的擴展以及區域監管差異的相互作用，帶來了不同的機會和挑戰。優先考慮互通性、人性化的設計和強大的製造能力的機構，將在贏得臨床醫生的信任和確保患者永續獲得治療方面佔據優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：慢性阻塞性肺病和氣喘治療設備市場：依設備類型分類

  • 乾粉吸入器
  • 定量吸入器
  • 噴霧器
    • 噴射式霧化器
    • 網狀霧化器
    • 超音波霧化器
  • 緩霧吸入器
  • 帶墊片和閥門的保持腔

第9章：慢性阻塞性肺病和氣喘治療設備市場：依適應症分類

  • 氣喘
  • COPD

第10章：慢性阻塞性肺病和氣喘治療設備市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第11章：慢性阻塞性肺病和氣喘治療設備市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：慢性阻塞性肺病和氣喘治療設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：慢性阻塞性肺病和氣喘治療設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：慢性阻塞性肺病和氣喘治療設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國慢性阻塞性肺病與氣喘治療設備市場

第16章：中國慢性阻塞性肺病與氣喘治療設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3M Company
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Ltd.
  • Fisher & Paykel Healthcare Corporation Limited
  • GlaxoSmithKline plc
  • Novartis International AG
  • OMRON Corporation
  • PARI Medical Holding GmbH
  • ResMed Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-535C62918B2C

The COPD & Asthma Devices Market was valued at USD 39.69 billion in 2025 and is projected to grow to USD 42.07 billion in 2026, with a CAGR of 6.09%, reaching USD 60.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 39.69 billion
Estimated Year [2026] USD 42.07 billion
Forecast Year [2032] USD 60.08 billion
CAGR (%) 6.09%

A compelling industry overview that situates device innovation, clinical expectations, and healthcare delivery pressures shaping COPD and asthma management today

The respiratory device landscape is at a pivotal inflection point, driven by converging clinical priorities and technological innovation that together redefine care delivery for chronic respiratory diseases. Advances in device mechanics, aerosol science, and digital adherence technologies are expanding the functional role of inhalation and nebulization systems beyond simple drug delivery to becoming integrated tools for monitoring, personalization, and outcomes measurement. Clinicians increasingly expect devices to support data capture that informs titration, exacerbation risk assessment, and remote care pathways, while patients demand ease of use, portability, and clear feedback on correct technique.

At the same time, healthcare systems face mounting pressure to improve cost-effectiveness and patient outcomes, prompting procurement and clinical leaders to weigh device performance against total cost of care and real-world effectiveness. This environment favors interoperable solutions and partnerships that bridge device manufacturers, pharmaceutical sponsors, and digital health providers. As a result, manufacturers are prioritizing human-centered design, regulatory robustness, and evidence generation to demonstrate adherence benefits and clinical impact, while payers and providers seek measurable improvements in utilization and disease control. In this context, the executive audience must balance near-term operational imperatives with long-term investments that position products as clinically relevant, digitally enabled tools in chronic respiratory care.

An in-depth synthesis of the critical structural shifts transforming COPD and asthma device development, adoption, and health system integration

The last several years have produced transformative shifts that alter how devices for COPD and asthma are developed, adopted, and reimbursed. First, digital integration has moved from a differentiator to a core expectation; connected inhalers, sensor-enabled spacers, and cloud-based adherence platforms now influence purchasing decisions and clinical pathways. This shift compels product teams to consider software ecosystems, cybersecurity, and data interoperability from the earliest design stages, and to adopt lifecycle strategies that include firmware updates and data governance.

Second, patient-centered care models and the expansion of home-based management have elevated the importance of device portability, simplicity, and remote monitoring capabilities. Consequently, device form factors and usability testing receive greater emphasis during development cycles, and clinical validation increasingly incorporates real-world evidence collected outside traditional clinic settings. Third, supply chain resilience and component sourcing have become strategic priorities as manufacturers diversify suppliers and pursue modular designs to mitigate disruptions. Fourth, regulatory authorities are refining guidance around combination products and digital health components, encouraging incremental evidence generation tied to safety and clinical performance. Collectively, these shifts foster closer collaboration across medical device engineering, clinical affairs, regulatory, and commercial teams, and demand that organizations adopt integrated roadmaps that synchronize product, data, and market access strategies.

A strategic analysis of how 2025 United States tariff policies have reshaped sourcing, production decisions, and distribution strategies across respiratory device value chains

The introduction of new tariff measures in the United States in 2025 has created a sustained strategic imperative for manufacturers, suppliers, and distributors to reassess international sourcing and trade-dependent cost structures. In response, many organizations have accelerated nearshoring efforts, redesign initiatives to substitute tariff-exposed components, and renegotiated supplier contracts to preserve margins while maintaining product performance and regulatory compliance. These adjustments are not simply transactional; they drive engineering design choices and inventory management policies that affect lead times and production flexibility.

Additionally, procurement teams are recalibrating vendor evaluation criteria to include trade risk and total landed cost, and contract manufacturers are positioning themselves as partners that can offer geographically diversified footprint options. For some device segments, particularly those that rely on precision polymers, microfluidic assemblies, or imported electronic sensors, the tariff environment has intensified efforts to localize final assembly or to validate alternative qualified suppliers. Downstream, distributors and pharmacy channels are adapting their pricing strategies and promotional tactics to offset increased acquisition costs while preserving patient access through co-pay support programs and payer negotiations. Ultimately, the cumulative impact of tariff policy has elevated supply chain strategy to a board-level consideration, requiring cross-functional coordination among R&D, procurement, quality, and commercial teams to safeguard continuity of care and maintain competitive positioning.

A nuanced breakdown of device, clinical, user, and distribution segment dynamics that reveals where product design and commercial focus will drive competitive advantage

Segment-level insights reveal differentiated demand dynamics, clinical considerations, and design priorities across device types, indications, end users, and distribution channels. Based on device type, attention is focused on Dry Powder Inhaler, Metered Dose Inhaler, Nebulizer, Soft Mist Inhaler, and Spacer And Valved Holding Chamber, with nebulizer innovation spanning Jet Nebulizer, Mesh Nebulizer, and Ultrasonic Nebulizer subtypes; each category presents distinct usability, maintenance, and aerosol performance trade-offs that influence clinician preference and patient adherence. Based on indication, the clinical pathways for Asthma and COPD require tailored device features, such as dose counters and breath-actuated mechanisms for asthma versus sustained-delivery or long-duration nebulization options favored in certain COPD management scenarios. Based on end user, clinic, home care, and hospital settings impose divergent requirements for device robustness, infection control, and serviceability, with home care particularly driving needs for intuitive interfaces and remote monitoring support. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each demand specific packaging, labeling, and fulfillment strategies, and the rising prominence of e-commerce is prompting manufacturers to rethink direct-to-patient logistics, warranty handling, and digital support materials. Together, these segmentation lenses clarify where product differentiation, clinical evidence, and commercial execution will be most impactful.

A comparative regional assessment revealing how geographic clinical practices, regulatory regimes, and supply chain footprints influence device adoption and market approaches

Regional insights underscore how geography shapes clinical practices, regulatory environments, and commercial models for respiratory devices. In the Americas, health systems and payer negotiations often emphasize cost containment and demonstrable outcomes, which rewards devices that yield measurable adherence improvements and reduced acute care utilization, while the presence of major contract manufacturers in the region supports localized production and rapid distribution. In Europe, Middle East & Africa, diverse regulatory pathways and heterogeneous reimbursement landscapes necessitate adaptive market access strategies, and the region's emphasis on public health infrastructure creates opportunities for devices that support large-scale adherence programs and telehealth-enabled disease management. In the Asia-Pacific region, rapid urbanization, expanding middle-class demand, and robust local manufacturing capabilities encourage design-for-scale approaches and competitive pricing, while investments in digital health adoption drive strong interest in connected devices and remote monitoring solutions.

Across all regions, local clinical guidelines, procurement norms, and patient preferences influence adoption patterns, and manufacturers that tailor product features, evidence generation strategies, and channel partnerships to each regional context will be better positioned to capture clinical trust and commercial traction. Moreover, cross-border regulatory harmonization initiatives and regional trade agreements present both opportunities and constraints that must be navigated carefully to optimize market entry and post-market support.

An insightful evaluation of competitive forces and collaboration trends that define how established firms, niche innovators, and digital entrants are shaping the respiratory device ecosystem

Competitive dynamics in the COPD and asthma device space reflect a mix of legacy medical device manufacturers, specialized inhaler innovators, electronic health technology developers, and agile contract manufacturers. Established manufacturers continue to leverage clinical relationships, regulatory experience, and scale to defend installed bases, while specialized firms compete on niche performance features, ergonomic design, and rapid iteration cycles. Digital health entrants and sensor-focused companies are reshaping expectations for adherence measurement and behaviorally informed interventions, prompting incumbents to pursue partnerships, licensing agreements, or in-house digital platform development to remain relevant.

Contract manufacturing and service providers have become strategic collaborators, offering capabilities in regulatory-compliant assembly, sterilization, and aftermarket servicing that enable original equipment manufacturers to focus on core product differentiation. Innovation is increasingly concentrated at the intersections of materials science, aerosol engineering, and embedded electronics, and intellectual property strategies now encompass both mechanical innovations and software-related algorithms. For commercial leaders, competitive advantage will hinge on the ability to demonstrate clinical value, integrate digital services, and scale manufacturing with resilient supply chains, while preserving agility to respond to regulatory guidance and payer expectations.

A pragmatic set of prioritized, cross-functional recommendations designed to convert device innovation and supply resilience into sustained clinical adoption and commercial performance

Industry leaders should adopt strategic moves that translate technological potential into measurable clinical and commercial outcomes. First, prioritize modular product architectures that allow for rapid component substitution and regional customization, thereby reducing exposure to trade disruptions and enabling faster regulatory filings. Second, invest in integrated digital solutions that pair device hardware with adherence analytics and clinician-facing dashboards, and design evidence-generation plans that capture real-world effectiveness and health-economic endpoints relevant to payers. Third, diversify manufacturing and supplier networks by qualifying multiple sources for critical components and by exploring regional assembly centers to shorten lead times and improve responsiveness.

Fourth, deepen collaborations with healthcare providers and pharmacy channels to embed devices within care pathways and to pilot value-based contracting models that align incentives around improved disease control. Fifth, enhance post-market support through scalable service models for maintenance, training, and remote troubleshooting, which will increase device longevity and patient satisfaction. Sixth, align regulatory and clinical affairs teams early in product development to ensure that digital and combination product claims are supported by appropriate evidence and documentation. By executing these steps in concert, organizations can strengthen resilience, accelerate adoption, and demonstrate the clinical and economic value necessary for durable market success.

A transparent and rigorous mixed-methods research approach combining clinician engagement, regulatory analysis, and supply chain mapping to ground practical insights and recommendations

The research methodology underpinning this analysis blends primary stakeholder engagement with comprehensive secondary synthesis to ensure balanced, actionable insights. Primary research included structured interviews with clinicians, respiratory therapists, procurement leaders, device engineers, and distribution partners to capture frontline perspectives on device performance, usability, and channel dynamics. These conversations informed hypothesis testing around clinical workflows, adherence barriers, and procurement priorities, and were complemented by site visits to observe device deployment in clinic, hospital, and home care settings.

Secondary research comprised a targeted review of peer-reviewed clinical literature, regulatory guidance documents, device safety communications, patent filings, and trade publications to validate technical assertions and to map emerging regulatory trends. Supply chain mapping and component sourcing analysis used customs and trade data alongside supplier disclosures to evaluate geographic exposures and mitigation strategies. Evidence synthesis prioritized triangulation across data sources, and methodological rigor was maintained through iterative validation with subject matter experts, ensuring that conclusions reflect practical realities and operational constraints.

A decisive conclusion that synthesizes how integrated device, digital, and supply chain strategies will determine long-term success in COPD and asthma care

In summary, the COPD and asthma device landscape is being reshaped by technological integration, shifting care models, and trade-related supply chain pressures. Devices are transitioning from single-function delivery tools to integrated components of chronic care ecosystems, demanding coordinated strategies across product engineering, clinical evidence generation, and commercial operations. The confluence of digital expectations, home-based care expansion, and regional regulatory nuances creates differentiated opportunities and challenges; organizations that prioritize interoperability, human-centered design, and resilient manufacturing will be better equipped to capture clinical trust and ensure sustained patient access.

Looking ahead, success will depend less on isolated product attributes and more on the ability to deliver measurable health outcomes through combined hardware, software, and service offerings. By aligning R&D priorities with payer and provider needs, diversifying supply chains, and forging partnerships that bridge technology and clinical practice, stakeholders can navigate current headwinds and unlock long-term value for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COPD & Asthma Devices Market, by Device Type

  • 8.1. Dry Powder Inhaler
  • 8.2. Metered Dose Inhaler
  • 8.3. Nebulizer
    • 8.3.1. Jet Nebulizer
    • 8.3.2. Mesh Nebulizer
    • 8.3.3. Ultrasonic Nebulizer
  • 8.4. Soft Mist Inhaler
  • 8.5. Spacer And Valved Holding Chamber

9. COPD & Asthma Devices Market, by Indication

  • 9.1. Asthma
  • 9.2. COPD

10. COPD & Asthma Devices Market, by End User

  • 10.1. Clinic
  • 10.2. Home Care
  • 10.3. Hospital

11. COPD & Asthma Devices Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. COPD & Asthma Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. COPD & Asthma Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. COPD & Asthma Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States COPD & Asthma Devices Market

16. China COPD & Asthma Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3M Company
  • 17.6. AstraZeneca plc
  • 17.7. Boehringer Ingelheim GmbH
  • 17.8. Chiesi Farmaceutici S.p.A.
  • 17.9. Cipla Ltd.
  • 17.10. Fisher & Paykel Healthcare Corporation Limited
  • 17.11. GlaxoSmithKline plc
  • 17.12. Novartis International AG
  • 17.13. OMRON Corporation
  • 17.14. PARI Medical Holding GmbH
  • 17.15. ResMed Inc.
  • 17.16. Sandoz International GmbH
  • 17.17. Sanofi S.A.
  • 17.18. Teva Pharmaceutical Industries Ltd.
  • 17.19. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COPD & ASTHMA DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COPD & ASTHMA DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY JET NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY JET NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY JET NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY MESH NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY MESH NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY MESH NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ULTRASONIC NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SOFT MIST INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SOFT MIST INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SOFT MIST INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SPACER AND VALVED HOLDING CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SPACER AND VALVED HOLDING CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY SPACER AND VALVED HOLDING CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY COPD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY COPD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY COPD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GCC COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NATO COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL COPD & ASTHMA DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA COPD & ASTHMA DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA COPD & ASTHMA DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA COPD & ASTHMA DEVICES MARKET SIZE, BY NEBULIZER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA COPD & ASTHMA DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA COPD & ASTHMA DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA COPD & ASTHMA DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)